Families with autosomal dominant inherited predisposition to gastric cancer have been
described. More recently, germlineE-cadherin/CDH1mutations have been identified in hereditary …

Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have
thus far been disappointing owing to a lack of robust stratification methods. Whole-genome …

E-cadherin germ-line mutations have recently been described as a molecular basis for early-onset
familial gastric cancer in Maori kindred. We screened 18 gastric cancer families of …

Cancer genome sequencing studies have identified numerous driver genes, but the relative
timing of mutations in carcinogenesis remains unclear. The gradual progression from …

Esophageal adenocarcinoma (EAC) incidence is increasing while 5-year survival rates
remain less than 15%. A lack of experimental models has hampered progress. We have …

Esophageal adenocarcinoma (EAC) is a poor-prognosis cancer type with rapidly rising
incidence. Understanding of the genetic events driving EAC development is limited, and there …

E-cadherin is involved in the formation of cell-junctions and the maintenance of epithelial
integrity. Direct evidence of E-cadherin mutations triggering tumorigenesis has come from the …

The International Gastric Cancer Linkage Consortium (IGCLC) predicted that up to 25% of
families fulfilling the criteria for hereditary diffuse gastric cancer (HDGC) would harbor CDH1 …

Background & Aims Most patients with esophageal adenocarcinoma (EAC) present with de
novo tumors. Although this could be due to inadequate screening strategies, the precise …

Background & Aims Esophageal adenocarcinomas (EACs) are heterogeneous and often
preceded by Barrett’s esophagus (BE). Many genomic changes have been associated with …